Variant histology of pediatric nodular lymphocyte‐predominant Hodgkin lymphoma with IgD and CD30 expression
Pediatric Blood & Cancer · 2023
DOI: 10.1002/pbc.30647 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2023. Verfasst von Nesreen Ali und 5 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Oncology and Hematology Department, National Cancer Institute (NCI), Cairo University and Children Cancer Hospital, Cairo, Egypt. Hauptthemen laut MEDLINE: Hodgkin Disease, Lymphoma, Follicular. Die Arbeit nennt 27 Literaturangaben.
Abstract (Originalsprache)
Background
Nodular lymphocyte‐predominant Hodgkin lymphoma (NLPHL), recently known as nodular lymphocyte‐predominant B‐cell lymphoma (NLPBL), accounts for 5%–10% of Hodgkin lymphoma (HL). Different morphologic patterns of NLPBL are identified and categorized as typical patterns (type A and B) and variant histologic patterns (types C, D, E, and F). Patients and method We investigated different morphologic patterns, CD30 and IgD expression in pediatric patients with NLPBL diagnosed at the Children's Cancer Hospital Egypt.
Results
Forty‐six (53%) of the patients exhibited a typical histologic pattern, whereas the remaining (47%) exhibited variant histologic pattern. Variant histology is associated with unfavorable clinical characteristics, such as advanced stages, B‐symptoms, and extranodal involvements, particularly bone marrow and bone infiltration, with p ‐values of .06, .05, and 0.01%, respectively. Additionally, 39% of patients with variant histology experienced disease progression or relapse, compared to only 15.2% of patients with typical patterns ( p = .009). Types C and D are related to decreased event‐free survival (EFS), as shown by a p ‐value of .05. The 5‐year EFS for patients with variant histology was 94.4% for the rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisone (RCHOP) versus 33.3% for the adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD). IgD expression in lymphocyte‐predominant (LP) cells was detected in 44 (50%) patients, while CD30 expression in LP cells was found in 39 (44%) patients.
Conclusion
Variant histology of NLPBL was associated with advanced disease stages and a poor prognosis, while expression of IgD and CD30 in LP cells was not. The poor outcome of variant histology improved with the RCHOP regimen.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pediatric Oncology and Hematology Department, National Cancer Institute (NCI), Cairo University and Children Cancer Hospital, Cairo, Egypt.
- Clinical Oncology Department, Menoufya University and Children Cancer Hospital Egypt, Cairo, Egypt.
- Pathology Department, National Cancer Institute (NCI), Cairo University and Children Cancer Hospital Egypt, Cairo, Egypt.
- Radiation Therapy Department, National Cancer Institute (NCI), Cairo University and Children Cancer Hospital Egypt, Cairo, Egypt.
- Clinical Research Department, Children Cancer Hospital, Cairo, Egypt.
- Pediatric Oncology and Hematology Department, National Cancer Institute (NCI), Cairo University, Egypt and Child Health Department, Sultan Qaboos University, Muscat, Oman.
ORCID-Profile: Nesreen Ali
Zitieren
APA
Ali, N., Moussa, E., Khorshed, E., Zaghloul, M. S., Elnashar, A., & Abdalla, A. (2023). Variant histology of pediatric nodular lymphocyte‐predominant Hodgkin lymphoma with IgD and CD30 expression. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.30647
Vancouver
Ali N, Moussa E, Khorshed E, Zaghloul MS, Elnashar A, Abdalla A. Variant histology of pediatric nodular lymphocyte‐predominant Hodgkin lymphoma with IgD and CD30 expression. Pediatric Blood & Cancer. 2023. doi:10.1002/pbc.30647
BibTeX
@article{Ali2023,
author = {Ali, Nesreen and Moussa, Emad and Khorshed, Eman and Zaghloul, Mohamed S and Elnashar, Amr and Abdalla, Amr},
title = {Variant histology of pediatric nodular lymphocyte‐predominant Hodgkin lymphoma with IgD and CD30 expression},
journal = {Pediatric Blood & Cancer},
year = {2023},
doi = {10.1002/pbc.30647}
}
EUVIMED